^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD79B mutation + TNFAIP3 mutation

    i
    Other names: CD79B, B-Cell Antigen Receptor Complex-Associated Protein Beta Chain, CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta, IGB, B29, CD79b Antigen (Immunoglobulin-Associated Beta), CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Antigen, AGM6, TNFAIP3, TNF Alpha Induced Protein 3, Tumor Necrosis Factor Alpha-Induced Protein 3, Putative DNA-Binding Protein A20, OTU Domain-Containing Protein 7C, Zinc Finger Protein
    Entrez ID:
    974; 7128
    Related biomarkers:
    Expression
    Mutation
    Others
    1year
    Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma. (PubMed, Hemasphere)
    Together, we demonstrate variable clonal B-cell dynamics in LPL/WM patients developing DLBCL, and the occurrence of clonally unrelated DLBCL in about one-quarter of LPL/WM patients. Moreover, we identified commonly mutated genes upon DLBCL transformation, which together with preserved mutations already present in LPL characterize the mutational landscape of DLBCL occurrences in LPL/WM patients.
    Journal
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD79B (CD79b Molecule) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • PIM1 (Pim-1 Proto-Oncogene) • BTG1 (BTG Anti-Proliferation Factor 1) • BTG2 (BTG Anti-Proliferation Factor 2)
    |
    TP53 mutation • MYD88 mutation • CXCR4 mutation • CD79B mutation • TNFAIP3 mutation • BTG1 mutation • CD79B mutation + TNFAIP3 mutation
    over2years
    The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. (PubMed, Hepatol Int)
    A better understanding of the composition of TIME in EBV-LELCC is critical for predicting the clinical outcomes of ICB treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PTEN (Phosphatase and tensin homolog) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • MUC16 (Mucin 16, Cell Surface Associated) • NCAM1 (Neural cell adhesion molecule 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • BARD1 (BRCA1 Associated RING Domain 1) • KDM5A (Lysine Demethylase 5A) • EPHA5 (EPH Receptor A5) • RECQL4( RecQ Like Helicase 4) • MUC6 (Mucin 6)
    |
    PD-L1 expression • PD-L1 overexpression • PTEN mutation • CD79B mutation • BARD1 mutation • TNFAIP3 mutation • CD79B mutation + TNFAIP3 mutation • RECQL4 mutation